Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors: A brief report.. Invest New Drugs 1995; 13(2): 163-165.
Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications. J Clin Oncol 1995; 13(5): 1195-1200.
Motzer R, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors. J Clin Oncol 1996; 14(4): 1098-1105.
Berg WJ, Schwartz L, Amsterdam A, Mazumdar M, Murray-Law T, Vlamis V, Nanus D, Motzer RJ. Clinical studies with 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 1997; 15(4): 353-355.
Motzer RJ, Amsterdam A, Prieto V, Sheinfeld J, Murty VV S, Mazumdar M, Bosl GJ, Chaganti RS K, Reuter VE. Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159(1): 133-138.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma treated at the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1999; 17(8): 2530-2540.
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bosl GJ, Motzer RJ. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002; 20(1): 297-301.
Amsterdam A, Kauff N, Castiel M. Managing menopause in the cancer patient. The Female Patient 2004; 29(6): 21-24.
Krychman M, Amsterdam A, Carlson E, Carter J, Castiel M. Women's cancer health in the 21st century: Sexuality, sexual expression and intimacy. The Female Patient: Primary Care Edition 2004; 29(3): 1-4.
Amsterdam A, Krychman M, Carlson E, Carter J, Castiel M. Women's cancer health in the 21st century: Sexuality, sexual expression and intimacy. The Female Patient: OB/GYN Edition 2004; 29(9): 1-4.